CRA Financial Services LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

CRA Financial Services LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 15.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,809 shares of the company’s stock after selling 2,001 shares during the quarter. CRA Financial Services LLC’s holdings in Johnson & Johnson were worth $1,789,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. MTM Investment Management LLC increased its holdings in Johnson & Johnson by 0.5% in the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after buying an additional 61 shares during the period. OneAscent Financial Services LLC increased its stake in shares of Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after acquiring an additional 63 shares during the period. Beech Hill Advisors Inc. raised its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after purchasing an additional 63 shares during the last quarter. FIDELIS iM LLC lifted its position in Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after purchasing an additional 64 shares during the period. Finally, Well Done LLC boosted its holdings in Johnson & Johnson by 0.4% in the first quarter. Well Done LLC now owns 15,584 shares of the company’s stock valued at $2,415,000 after purchasing an additional 64 shares during the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on JNJ shares. Citigroup began coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Barclays cut their target price on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a report on Friday, September 8th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Finally, Morgan Stanley cut their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating for the company in a report on Thursday, August 31st. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $170.65.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ opened at $162.41 on Tuesday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The stock has a market cap of $422.10 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 3.26 and a beta of 0.54. The firm’s fifty day moving average is $166.21 and its two-hundred day moving average is $161.83. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same period in the previous year, the business posted $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.03 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. Johnson & Johnson’s payout ratio is 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.